AXIM Stock Analysis
AX
Uncovered
Axim Biotechnologies Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
AXIM Biotechnologies, Inc. operates as a biotechnology company. The company is headquartered in San Diego, California and currently employs 6 full-time employees. The company went IPO on 2013-04-09. The firm is focused on diagnosis and treatment for oncology and SARS-CoV-2, or COVID-19. The firm's COVID-19 rapid neutralizing antibody test ImmunoPass is the rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering human host cells. In addition, the Company is developing rapid diagnostic tests for the early detection of cancer and small molecules drugs to treat cancer and block metastasis. The firm's lead product candidate, SPX-1009, which is an anti-metastatic treatment and to measure levels of Quiescin Sulfhydryl Oxidase 1 (QSOX1) related to cancer. The firm is also engaged in point-of-care (POC) lab testing systems designed to assist eye-care physicians in detecting and quantifying a variety of biomarkers associated with external ocular disorders.